U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C13H17NO2
Molecular Weight 219.2796
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALMINOPROFEN

SMILES

CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1

InChI

InChIKey=FPHLBGOJWPEVME-UHFFFAOYSA-N
InChI=1S/C13H17NO2/c1-9(2)8-14-12-6-4-11(5-7-12)10(3)13(15)16/h4-7,10,14H,1,8H2,2-3H3,(H,15,16)

HIDE SMILES / InChI
Molecular Formula C13H17NO2
Molecular Weight 219.2796
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. It has anti-inflammatory properties different from the classical NSAID. Alminoprofen possesses both antiphospholipase A2 (PLA2) activity and anti-cycloxygenase (COX) activity.

CNS Activity

CNS Active
4,002

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Cyclooxygenase-2
201
Inhibitor
8,504
Secretory phospholipase A2, Homo sapiens
3
Inhibitor
8,504
Cyclooxygenase-1
131
Inhibitor
8,504

Conditions

ConditionModalityTargetsHighest PhaseProduct
Pain
619
 Palliative
Approved
8,583
Minalfen
Inflammation
105
 Primary
Approved
8,583
Minalfen

Cmax

ValueDoseCo-administeredAnalytePopulation
24.2 mg/L
300 mg 3 times / day steady-state, oral
 ALMINOPROFEN plasma
Homo sapiens
9.3 mg/L
300 mg 3 times / day steady-state, oral
 ALMINOPROFEN unknown
Homo sapiens
39.2 mg/L
300 mg single, oral
 ALMINOPROFEN plasma
Homo sapiens
16.1 μg/mL
200 mg single, oral
 ALMINOPROFEN plasma
Homo sapiens
21.6 μg/mL
200 mg 3 times / day steady-state, oral
 ALMINOPROFEN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
58.5 μg × h/mL
200 mg single, oral
 ALMINOPROFEN plasma
Homo sapiens
58.1 μg × h/mL
200 mg 3 times / day steady-state, oral
 ALMINOPROFEN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
300 mg single, oral
 ALMINOPROFEN plasma
Homo sapiens
2.45 h
200 mg single, oral
 ALMINOPROFEN plasma
Homo sapiens
2.49 h
200 mg 3 times / day steady-state, oral
 ALMINOPROFEN plasma
Homo sapiens

Doses

PubMed

Patents

US2016089478
3
US2016090381
3

Sample Use Guides

In Vivo Use Guide
In rheumatoid arthritis and spondylosis deformans - 200 mg (three times a day) repeated dose for 5 days.
Route of Administration: Oral
In Vitro Use Guide
Alminoprofen (10(-6)-10(-4) M) inhibited dose-dependently the chemotaxis of leukocytes induced by chemotactic factors from guinea pig neutrophils stimulated with sodium urate crystals.
Substance Class Chemical
Record UNII
0255AHR9GJ
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966